Account
Watchlists
Bookmarks
Pricing
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Bearish
5
Neutral
4
Bullish
5
Bearish
5
Neutral
4
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Investor Presentation
Q4 FY23
Investor Presentation
Q1 FY22
Investor Presentation
Q4 FY21
Investor Presentation
Q3 FY21
Investor Presentation
Q2 FY21
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Market Cap
₹ 72 Cr
P/E
22.64
EOGM Announcement
4 days ago
Extra-Ordinary General Meeting Scheduled
The company will hold its 01st Extra-Ordinary General Meeting for FY 2025-26 on January 7, 2026, via video conference.
Extra-Ordinary General Meeting
5 days ago
Eiko Lifesciences EOGM Scheduled for January 2026
Eiko Lifesciences Limited announced their 01st Extra-Ordinary General Meeting on January 7, 2026, to approve the preferential issuance of 33,00,000 warrants convertible into equity shares.
Press Release
5 days ago
Eiko Lifesciences Acquires 51% in SSM Formulations
Eiko Lifesciences Limited announces the acquisition of a 51% equity stake in SSM Formulations Private Limited, enhancing its pharmaceutical capabilities.
Fundraising Announcement
6 days ago
Eiko LifeSciences to Raise Funds through Equity and Warrant Issues
Eiko LifeSciences Limited plans to raise funds by issuing 3.3 million Warrants and 675,000 Equity Shares at Rs. 55 each on a preferential basis, subject to shareholder approval at the upcoming EGM.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
41.35 | 100 Cr | 19.94 | 1.07 | 0.00 | 5.34 | 7.69 | 3.49 | |
57.00 | 99 Cr | 24.46 | 2.17 | 0.00 | 6.64 | 7.76 | 4.18 | |
42.90 | 84 Cr | 14.21 | 0.94 | 0.00 | 6.79 | 8.81 | 5.95 | |
2055.00 | 83 Cr | 14.03 | 1.74 | 0.97 | 12.37 | 18.78 | 13.63 | |
105.00 | 80 Cr | — | 1.66 | 0.00 | 1.11 | 8.59 | 0.55 | |
53.76 | 72 Cr | 22.64 | 1.23 | 0.00 | 5.86 | 9.26 | 6.11 | |
19.68 | 52 Cr | — | 0.06 | 0.00 | -0.91 | -0.60 | -0.46 |
Eiko Lifesciences Limited specializes in manufacturing and exporting specialty chemicals and pharma intermediates, serving both Indian and global markets.
Originally founded as Narendra Investments (Delhi) Limited, the company shifted to its current name and business focus in 2021, marking a significant transformation.
Since commencing specialty and fine chemicals production in 2020, Eiko has rapidly scaled operations and expanded its brand and customer base, emerging as a fast-growing player in India.
In 2022, Eiko launched new molecules targeting agrochemical intermediates, polymer science, and pharmaceuticals, showcasing its innovation capabilities.
The company diversified into applications for agrochemical, personal care, and food industries in 2023, broadening its product range.
Chemicals
Chemicals - Speciality - Medium / Small
72 Cr
Moderate Risk
22.6
28.8
0.6
1.2
74.88
42.00
Sales CAGR
1Y
16.33%
3Y
8.54%
5Y
—
10Y
57.04%
Profit CAGR
1Y
132.00%
3Y
35.12%
5Y
68.60%
10Y
40.83%
ROE
TTM
5.86%
3Y
2.39%
5Y
2.58%
10Y
2.60%
ROCE
TTM
9.26%
3Y
3.41%
5Y
3.91%
10Y
3.92%
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
MODERATE RISK
